Journal for immunotherapy of cancer · 2026
Liver-directed AAV-IL-10 therapy enhances CD8+ T cell-mediated immunity against hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Chia-I, Chiu Yi-Wei, Yen Meng-Syuan, Wang Yu-Wen, Wu Ying-Hsuan, Chuang Ya-Hui
Аннотация
BACKGROUND: The liver's inherently immunosuppressive microenvironment presents a major barrier to effective immunotherapy for hepatocellular carcinoma (HCC). Although interleukin-10 (IL-10) has demonstrated antitumor activity in several cancer models, its therapeutic potential in HCC remains unclear. Here, we investigated whether liver-directed delivery of IL-10 using an adeno-associated virus vector (AAV-IL-10) could enhance antitumor immunity in HCC.
METHODS: Syngeneic orthotopic and intrahepatic metastatic HCC mouse models were used to evaluate the effects of liver-directed AAV-IL-10 therapy. Tumor burden, immune cell infiltration, and functional activation were assessed by flow cytometry and related analyses.
RESULTS: Liver-directed AAV-IL-10 treatment significantly reduced intrahepatic tumor burden and promoted robust infiltration of CD8+ T cells into the tumor microenvironment. AAV-IL-10 enhanced the functional activation of natural killer cells and CD8+ T cells, as reflected by increased expression of effector cytokines and cytotoxic molecules. Notably, AAV-IL-10 augmented the effector capacity of terminally exhausted CD8+ tumor-infiltrating lymphocytes and expanded a population of CD8+ T cells with a tissue-resident memory (Trm)-like phenotype. These Trm-like CD8+ T cells were liver-resident and persisted after tumor clearance. Importantly, the antitumor effects of AAV-IL-10 were confined to the liver and did not affect the growth of distant subcutaneous tumors.
CONCLUSIONS: Liver-directed AAV-IL-10 delivery overcomes local immunosuppression and enhances CD8+ T cell-mediated antitumor immunity in murine HCC models. These findings support targeted IL-10 delivery as a promising strategy to improve immunotherapy outcomes in liver cancer.
METHODS: Syngeneic orthotopic and intrahepatic metastatic HCC mouse models were used to evaluate the effects of liver-directed AAV-IL-10 therapy. Tumor burden, immune cell infiltration, and functional activation were assessed by flow cytometry and related analyses.
RESULTS: Liver-directed AAV-IL-10 treatment significantly reduced intrahepatic tumor burden and promoted robust infiltration of CD8+ T cells into the tumor microenvironment. AAV-IL-10 enhanced the functional activation of natural killer cells and CD8+ T cells, as reflected by increased expression of effector cytokines and cytotoxic molecules. Notably, AAV-IL-10 augmented the effector capacity of terminally exhausted CD8+ tumor-infiltrating lymphocytes and expanded a population of CD8+ T cells with a tissue-resident memory (Trm)-like phenotype. These Trm-like CD8+ T cells were liver-resident and persisted after tumor clearance. Importantly, the antitumor effects of AAV-IL-10 were confined to the liver and did not affect the growth of distant subcutaneous tumors.
CONCLUSIONS: Liver-directed AAV-IL-10 delivery overcomes local immunosuppression and enhances CD8+ T cell-mediated antitumor immunity in murine HCC models. These findings support targeted IL-10 delivery as a promising strategy to improve immunotherapy outcomes in liver cancer.